Interval to biochemical failure is prognostic for distant metastases after salvage radiation therapy for prostate cancer
Tóm tắt
We assessed the prognostic value of the interval to biochemical failure (IBF) after salvage radiation therapy (SRT) following radical prostatectomy (RP) for prostate cancer to identify patients at high risk for distant metastasis (DM), prostate cancer-specific mortality (PCSM), and overall mortality (OM). From 1991 and 2007, 222 men with T2a-4a, N0/X, M0 prostate cancer received SRT for a rising PSA after RP. Of these, 48 experienced BF. Univariate and multivariate analyses (UVA, MVA, respectively) included initial PSA; T-stage; RT dose; nadir PSA; risk group; IBF; time from surgery to SRT; seminal vesicle invasion; Gleason score; and PSA doubling time. Median follow-up from SRT was 67 months. The median IBF was 33 months (range, 4–96). On UVA, IBF < 12 or <18 months and risk group predicted for DM, PCSM, and OM (p < 0.05). On MVA, IBF < 12 or <18 months predicted for DM (HRs 36.1, 15.3, respectively, p = 0.02). The 5-year DM, PCSM, and OM rates for an IBF of < vs. ≥18 months were 50 vs. 17 %, 45 vs. 0 %, 53 vs. 0 %, respectively (all p < 0.01). Patients with IBF < 18 months are at significantly higher risk of DM and death from prostate cancer. The IBF may be used to guide patients and physicians considering the initiation of salvage ADT. Furthermore, an IBF < 18 months could be used to select “high-risk” patients for clinical trials investigating novel salvage systemic therapy.
Tài liệu tham khảo
Bianco FJ Jr, Scardino PT, Eastham JA (2005) Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (“Trifecta”). Urology 66(5 Suppl):83–94
Stephenson AJ, Scardino PT, Kattan MW et al (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25(15):2035–2041
Leventis AK, Shariat SF, Kattan MW et al (2001) Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 19(4):1030–1039
Stephenson AJ, Shariat SF, Zelefsky MJ et al (2004) Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA, J Am Med Assoc 291(11):1325–1332
Song DY, Thompson TL, Ramakrishnan V et al (2002) Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology 60(2):281–287
Buyyounouski MK, Pickles T, Kestin LL et al (2012) Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. J Clin Oncol 30(15):1857–1863
Johnson S, Jackson W, Li D et al (2013) The interval to biochemical failure is prognostic for metastasis, prostate cancer-specific mortality, and overall mortality after salvage radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 86(3):554–561
Pollack A, Hanlon AL, Horwitz EM et al (2006) Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 64(2):518–526
Freedland SJ, Humphreys EB, Mangold LA et al (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294(4):433–439
Zaorsky NG, Yamoah K, Thakur ML et al (2014) A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer. Future Oncol 10(3):457–474
Zaorsky NG, Raj GV, Trabulsi EJ et al (2013) The dilemma of a rising prostate-specific antigen level after local therapy: what are our options? Semin Oncol 40(3):322–336
Den RB, Yousefi K, Trabulsi EJ et al (2015) Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol 33(8):944–951
Hurwitz MD, Zang Q, Sartor O et al (2014) Adjuvant radiation, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: results of RTOG 0621. Int J Radiat Oncol 90(1):S2